(KROS) Keros Therapeutics - Ratings and Ratios

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for disorders related to the transforming growth factor-beta (TGF-β) family of proteins. The companys pipeline includes several promising candidates, with KER-050 being the lead product, targeting low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis.

The companys product portfolio is diversified across various therapeutic areas, including hematology and cardiovascular disorders. KER-012, currently in Phase II clinical trials, shows potential in treating pulmonary arterial hypertension, while KER-065, in Phase I, is being developed for neuromuscular diseases. This diversification reduces the companys reliance on a single product and increases its potential for long-term growth.

Keros Therapeutics has established a strategic partnership with Hansoh (Shanghai) Healthtech Co., Ltd. to develop and commercialize elritercept, further expanding its reach in the global market. With its headquarters in Lexington, Massachusetts, the company is well-positioned to leverage the regions rich biotech ecosystem.

Analyzing the , KROSs current price is $13.51, with its short-term moving averages (SMA20 and SMA50) indicating a potential stabilization around $14.00. However, the SMA200 at $28.63 suggests a significant long-term downtrend. The Average True Range (ATR) of 0.51, equivalent to 3.79%, indicates moderate volatility. Given the 52-week high of $70.00 and low of $9.55, the stock has experienced significant price fluctuations.

Considering the , Keros Therapeutics has a market capitalization of $550.74M USD, with a forward P/E ratio of 49.02, indicating high growth expectations. The absence of a current P/E ratio is consistent with the company being in a clinical-stage, pre-revenue or with significant R&D expenses. The Return on Equity (RoE) of 0.75 suggests that the company is not yet generating significant profits from shareholder equity.

Forecasting KROSs future performance, we can expect the stock to experience significant price movements based on clinical trial results and regulatory updates. If KER-050, KER-012, or KER-065 demonstrate positive efficacy and safety data, the stock could potentially surge. Conversely, negative trial results or regulatory setbacks could lead to a decline in stock price. Based on the current technical and fundamental analysis, a potential price target for KROS could be in the range of $20-$30 in the next 6-12 months, contingent upon successful clinical trial outcomes and strategic partnerships.